Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients. (26th July 2022)

• Record Type: Journal Article
• Authors: Gualano, Bruno; Lemes, Ítalo Ribeiro; da Silva, Rafael Pires; Pinto, Ana Jéssica; Mazzolani, Bruna Caruso; Smaira, Fabiana Infante; Sieczkowska, Sofia Mendes; Aikawa, Nádia Emi; Pasoto, Sandra; Medeiros‐Ribeiro, Ana Cristina; Saad, Carla; Yuk, Emily; Silva, Clovis; Swinton, Paul; Hallal, Pedro Curi; Roschel, Hamilton; Bonfa, Eloisa
• Is Part Of: Scandinavian journal of medicine & science in sports. Volume 32:Number 10(2022)
• Page Start: 1510
• Page End: 1515
• Publication Date: 2022-07-26
• Subjects: autoimmune rheumatic disease -- COVID‐19 -- immunosuppression -- physical activity -- vaccine responses; Sports medicine -- Periodicals; Sports -- Physiological aspects -- Periodicals; Sports -- Periodicals; 617.1027
• DOI: 10.1111/sms.14213
• Languages: English
• ISSNs: 0905-7188

Abstract

Abstract : This prospective cohort study within an open‐label, single‐arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti‐SARS‐CoV‐2 antibodies 6 months after two‐dose schedule of CoronaVac in autoimmune rheumatic diseases (ARD) patients ( n = 748). Persistent immunogenicity 6 months after the full‐course vaccination was assessed using seroconversion rates of total anti‐SARS‐CoV‐2 S1/S2 IgG, geometric mean titers of anti‐S1/S2 IgG (GMT), and frequency of positive neutralizing antibodies (NAb). Physical activity was assessed trough questionnaire. Adjusted point estimates from logistic regression models indicated that physically active patients had greater odds of seroconversion rates (OR: 1.5 [95%CI: 1.1 to 2.1]) and NAb positivity (OR: 1.5 [95%CI: 1.0 to 2.1]), and approximately 43% greater GMT (42.8% [95%CI: 11.9 to 82.2]) than inactive ones. In conclusion, among immunocompromised patients, being physically active was associated with an increment in antibody persistence through 6 months after a full‐course of an inactivated SARS‐CoV‐2 vaccine.